DAFNA Capital Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

DAFNA Capital Management’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-660,000	Closed	-$318K	–	79
2023 Q2	$318K	Hold	660,000	–	–	0.09%	67
2023 Q1	$416K	Hold	660,000	–	–	0.12%	62
2022 Q4	$302K	Hold	660,000	–	–	0.09%	67
2022 Q3	$548K	Buy	+660,000	New	+$745K	0.15%	67

Other funds holding MDNA

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LBA

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MCWS

McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return

DAFNA Capital Management's MDNA Position: Q3 2023 in Review

DAFNA Capital Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q3 2023, closing a stake of 660,000 shares — an estimated $318K sold.

DAFNA Capital Management first reported a position in MDNA in Q3 2022 and held it in 4 quarters. The position peaked at $548K in Q3 2022. 25 funds tracked by Wall St. Rank hold MDNA as of Q3 2023.

DAFNA Capital Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q3 2023 after selling out during the quarter.
DAFNA Capital Management sold 660,000 Medicenna Therapeutics Corp. Common Shares shares in Q3 2023, an estimated $318K.
DAFNA Capital Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2022 and held it in 4 quarters.
DAFNA Capital Management's Medicenna Therapeutics Corp. Common Shares position peaked at $548K in Q3 2022.
25 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q3 2023.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.